Video
Dr. Mims on the Current Challenges With Myelofibrosis
Author(s):
Alice S. Mims, MD, assistant professor of medicine, Ohio State University Comprehensive Cancer Center, discusses the current challenges with myelofibrosis.
Alice S. Mims, MD, assistant professor of medicine, Ohio State University Comprehensive Cancer Center, discusses the current challenges with myelofibrosis.
Most patients are not candidates for allogeneic transplants, which is the only myelofibrosis therapy. In addition, there is no therapy that has proven to reverse fibrosis.
Only about 10% to 20% of patients with myelofibrosis show signs of myelofibrosis risk factors prior to diagnosis. The risk factor is if you have another myeloid malignancy, specifically myeloproliferative disorders, such as polycythemia vera or essential thrombocythemia.
